P01.110 Elderly patients 65years of age with newly diagnosed Glioblastoma multiforme gain life time from treatment with Tumor Treating Fields and Temozolomide

摘要

BackgroundGlioblastoma (GBM) is the most aggressive form of primary brain cancer in adults. The EF-14 trial was the first randomized controlled trial to report a survival benefit for newly diagnosed GBM patients in more than a decade with a survival rate greater than 10% at 5-years. A post hoc subgroup analysis of the elderly (>65 years) EF-14 populationshowed the greatest survival beneft from TTFields in this subgroup (HR = 0.51) and a survival at 5-years of 15% for patients treated with TTFields and maintenance TMZ compared to no survivors in the TMZ alone arm.